Unichem consolidated PAT turns to ₹41.5 Cr from year-ago loss as revenue climbs 20% YoY

Unichem Laboratories' consolidated (primary) results show a clear year-on-year turnaround: Q1 FY27 revenue rose 20.1% YoY to ₹632.62 Cr (from ₹526.60 Cr) and net profit swung to ₹41.47 Cr from a ₹10.47 Cr loss in Q1 FY26. Sequentially the print was also strong — revenue up 10.0% and PAT up ~280% over Q4 FY26's ₹575.12 Cr / ₹10.91 Cr — though that base included a ₹12.36 Cr one-off employee-benefit provision (New Labour Codes) that is absent this quarter, so part of the QoQ jump is a clean-base effect rather than fresh momentum. The margin story is the real driver: consolidated NPM expanded to 6.4% of total income from -2.0% a year ago and 1.8% last quarter, and pre-exceptional PBT margin swung to +7.7% of revenue from -1.7% YoY. The bridge is cost of materials consumed falling to 30.0% of revenue (₹190.02 Cr) from 41.3% (₹217.48 Cr) a year ago, even as revenue grew — a meaningful raw-material/mix improvement — partly offset by other expenses rising 12.6% YoY to ₹170.78 Cr. Employee costs were roughly flat (₹103.31 Cr vs ₹107.42 Cr YoY). The basis matters here: standalone (India) revenue actually declined 4.7% YoY to ₹366.27 Cr, and standalone PAT of ₹5.53 Cr was entirely a function of ₹16.72 Cr other income — on core operations alone, standalone expenses (₹375.61 Cr) exceeded revenue. The consolidated beat is thus concentrated overseas: auditors note the US subsidiary and UK-based Niche Generics together booked ₹470.28 Cr of revenue and ₹12.39 Cr of PAT this quarter, reviewed by other (non-principal) auditors. We have no formal management guidance on record and no prior concall read to check this print against, and no solid Street consensus for this specific quarter turned up in search — so vsGuidance and vsStreet are both marked unknown rather than assumed. Company events this quarter were largely procedural (AGM notice, board meeting notice) aside from a partial GSTR TRAN-1 credit allowance from CGST appellate authorities on 29th July 2026, whose P&L impact, if any, isn't quantified in this filing. Going forward, the print sets up three things to track: whether the standalone (domestic) business returns to organic profitability without leaning on other income, whether the outsized overseas contribution (₹470.28 Cr) is a sustainable run-rate or a one-quarter spike, and whether the raw-material cost improvement (30.0% of revenue) holds as input costs and product mix normalize.